Fig. 6.

Changes in CD8⁺ T cells in teplizumab-treated participants. (a) The number of circulating CD8CM (CD8⁺CD45RO⁺CD62L−) T cells (mean±SEM) is shown in teplizumab-treated responders (circles, n=13) and non-responders (squares, n=18) after drug treatment, corrected for the baseline counts. The baseline count of CD8CM cells was (mean±SEM) 0.011±0.002×10⁹ cells/l in non-responders and 0.014±0.003×10⁹ cells/l in responders. The number of cells was increased in responders at month 2 compared with the non-responders (**p=0.018, drug treated responders vs non-responders). (b) The corresponding CD4CM T cell counts (circles, responders; squares, non-responders) are shown. Significant changes in this subpopulation were not detected. (c) FACS plots showing CD8CM T cells before and at month 2 in representative drug- and placebo (Pcbo)-treated participants. The baseline count of CD4CM T cells was 0.12±0.013×10⁹cells/l in non-responders and 0.12±0.017×10⁹ cells/l in responders. The staining for CD45RO and CD62L is shown on gated CD8⁺ lymphocytes. In the data from a representative drug-treated participant shown, the percentage of CD8CM and EM cells (in the corresponding L quadrants) increased from 6.9% and 16% of CD8⁺ T cells to 19.1% and 19.4% of CD8⁺ T cells, respectively, whereas in the placebo-treated patient, the CD8CM and EM cells were 3% and 4.8% before and 2.5% and 3.7% after treatment